Methotrexate for treating rheumatoid arthritis

Pattern and Predictors of Infection Among Patients With Rheumatological Disease on Immunosuppressive Medications: A Retrospective Study in a Tertiary Care Hospital in Bangladesh

“…Several observational cohort studies have demonstrated similar associations [13,14]. Among the conventional synthetic DMARD (methotrexate, sulfasalazine, leflunomide, and hydroxychloroquine) hydroxychloroquine has the best safety profile related to infection whereas meta-analyses of observational studies and randomized trials related to methotrexate have shown conflicting results; some have found no elevated risk of infection, serious infection or OI, but others have demonstrated a modest increase in risk [15,16]. We also observed a similar pattern of safety profile among csDMARD.…”

Pattern and Predictors of Infection Among Patients With Rheumatological Disease on Immunosuppressive Medications: A Retrospective Study in a Tertiary Care Hospital in Bangladesh

“…Several observational cohort studies have demonstrated similar associations [13,14]. Among the conventional synthetic DMARD (methotrexate, sulfasalazine, leflunomide, and hydroxychloroquine) hydroxychloroquine has the best safety profile related to infection whereas meta-analyses of observational studies and randomized trials related to methotrexate have shown conflicting results; some have found no elevated risk of infection, serious infection or OI, but others have demonstrated a modest increase in risk [15,16]. We also observed a similar pattern of safety profile among csDMARD.…”

Merging Veterans Affairs rheumatoid arthritis registry and pharmacy data to assess methotrexate adherence and disease activity in clinical practice

“…In all groups, the mean MTX dose prescribed, 16 mg per week, was within the established standard of care and consistent with doses employed in recent RA clinical trials (6). In the high MTX adherence groups, the observed dose (the estimated dose that the patient actually received), approximated the prescribed dose of 16 mg per week.…”

Tumor necrosis factor-alpha inhibitor combined with methotrexate for ankylosing spondylitis: a systematic review and meta-analysis

“…We have conducted another systematic review comparing MTX with no MTX in AS and did not find any benefit, which was quite different from that in RA. 30,31 Perhaps the present review would further prove that MTX offer no benefit to AS patients, whether or not combined with TNFinhibitor. It is in consonance with ASAS/ EULAR recommendations on AS management.…”

Pattern and Predictors of Infection Among Patients With Rheumatological Disease on Immunosuppressive Medications: A Retrospective Study in a Tertiary Care Hospital in Bangladesh

“…Several observational cohort studies have demonstrated similar associations [13,14]. Among the conventional synthetic DMARD (methotrexate, sulfasalazine, leflunomide, and hydroxychloroquine) hydroxychloroquine has the best safety profile related to infection whereas meta-analyses of observational studies and randomized trials related to methotrexate have shown conflicting results; some have found no elevated risk of infection, serious infection or OI, but others have demonstrated a modest increase in risk [15,16]. We also observed a similar pattern of safety profile among csDMARD.…”

Merging Veterans Affairs rheumatoid arthritis registry and pharmacy data to assess methotrexate adherence and disease activity in clinical practice

“…In all groups, the mean MTX dose prescribed, 16 mg per week, was within the established standard of care and consistent with doses employed in recent RA clinical trials (6). In the high MTX adherence groups, the observed dose (the estimated dose that the patient actually received), approximated the prescribed dose of 16 mg per week.…”

Tumor necrosis factor-alpha inhibitor combined with methotrexate for ankylosing spondylitis: a systematic review and meta-analysis

“…We have conducted another systematic review comparing MTX with no MTX in AS and did not find any benefit, which was quite different from that in RA. 30,31 Perhaps the present review would further prove that MTX offer no benefit to AS patients, whether or not combined with TNFinhibitor. It is in consonance with ASAS/ EULAR recommendations on AS management.…”

Pattern and Predictors of Infection Among Patients With Rheumatological Disease on Immunosuppressive Medications: A Retrospective Study in a Tertiary Care Hospital in Bangladesh

“…Several observational cohort studies have demonstrated similar associations [13,14]. Among the conventional synthetic DMARD (methotrexate, sulfasalazine, leflunomide, and hydroxychloroquine) hydroxychloroquine has the best safety profile related to infection whereas meta-analyses of observational studies and randomized trials related to methotrexate have shown conflicting results; some have found no elevated risk of infection, serious infection or OI, but others have demonstrated a modest increase in risk [15,16]. We also observed a similar pattern of safety profile among csDMARD.…”

Merging Veterans Affairs rheumatoid arthritis registry and pharmacy data to assess methotrexate adherence and disease activity in clinical practice

“…In all groups, the mean MTX dose prescribed, 16 mg per week, was within the established standard of care and consistent with doses employed in recent RA clinical trials (6). In the high MTX adherence groups, the observed dose (the estimated dose that the patient actually received), approximated the prescribed dose of 16 mg per week.…”

Tumor necrosis factor-alpha inhibitor combined with methotrexate for ankylosing spondylitis: a systematic review and meta-analysis

“…We have conducted another systematic review comparing MTX with no MTX in AS and did not find any benefit, which was quite different from that in RA. 30,31 Perhaps the present review would further prove that MTX offer no benefit to AS patients, whether or not combined with TNFinhibitor. It is in consonance with ASAS/ EULAR recommendations on AS management.…”